Skip to main content
Biosenta Inc. logo

Biosenta Inc. — Investor Relations & Filings

Ticker · ZRO ISIN · CA09072N2023 CSE Manufacturing
Open in API
Filings indexed 152 across all filing types
Latest filing 2020-01-20 Regulatory Filings
Country CA Canada
Listing CSE ZRO

About Biosenta Inc.

https://www.biosenta.com

Biosenta Inc. develops, manufactures, and sells innovative, eco-friendly antimicrobial chemical compounds utilizing encapsulated nanotechnology. The company specializes in producing state-of-the-art solutions designed to eliminate harmful microorganisms for household and industrial applications. Biosenta's product portfolio includes Tri-Filler, a revolutionary anti-microbial filler used in soft and hard textiles. The company focuses on setting new global standards by delivering effective cleaning and material solutions that prioritize human and environmental safety.

Recent filings

Filing Released Lang Actions
52-109F1R - Certification of refiled annual filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification filed by the CEO of Biosenta Inc. regarding the refiled annual Management Discussion and Analysis (MD&A) for the years ended September 30, 2018 and 2017. It explicitly states it is a certificate under National Instrument 52-109, which relates to certification of disclosure in annual and interim filings. The document contains no actual financial data or detailed financial statements but is a formal attestation about the accuracy and fair presentation of the annual filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the actual annual report or MD&A. The document length is short (3233 characters), and it is a certification rather than the report itself.
2020-01-20 English
Annual MD&A (amended) - English.pdf
Management Reports Classification · 95% confidence The document is a detailed Management Discussion and Analysis (MD&A) for the years ended September 30, 2018 and 2017, including corrections and revisions to a previously filed MD&A. It discusses business strategy, intellectual property, impairment losses, product launches, joint ventures, and financial conditions. The text explicitly identifies itself as a "Revised Management Discussion and Analysis" and contains substantive financial and operational information, not just an announcement or summary. It is not a full Annual Report (10-K) but a Management Report explaining financial results and business trends. Therefore, the document fits the category of Management Reports (MDA).
2020-01-20 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.